Genentech Launches First Direct-to-Patient Program To Improve Affordable Access To Xofluza Nationwide

Genentech, a member of the Roche Group, announced the launch of its first Direct-to-Patient (DTP) program in the United States, designed to improve affordability and accessibility of Xofluza® (baloxavir marboxil) — a single-dose oral antiviral for treating and preventing influenza in patients aged five years and older. The initiative aligns with broader efforts to make medicines more affordable for Americans, particularly for those without insurance, with limited coverage, or whose plans exclude Xofluza.

Through partnerships with Alto Pharmacy Powered by Fuze Health, Amazon Pharmacy, and Mark Cuban Cost Plus Drug Company, PBC, Genentech is offering patients several cost-saving and convenience options. Eligible individuals can access Xofluza for $50 cash pay, roughly 70% below list price, via Alto Pharmacy and Cost Plus Drugs. Same-day home delivery is available in select regions through Alto and Amazon, while nationwide mail delivery supports prophylactic use for flu prevention.

“This new approach will allow for convenient, same-day delivery of our vital flu treatment in select U.S. markets,” said Ashley Magargee, chief executive officer of Genentech. “Expanding our distribution for Xofluza will allow us to reach more patients where they are increasingly interested in seeking their medicines.” 

The new program comes as the U.S. faces one of its most severe flu seasons since 2017–18, with an estimated 47–82 million cases and up to 130,000 deaths, according to the CDC. Genentech has also expanded its Xofluza coupon program, allowing eligible patients to pay as little as $35 for their prescription, with savings applied automatically at most participating pharmacies. Together, these measures aim to ease financial barriers and promote timely access to antiviral treatment.